Navigation Links
Milestone Scientific Receives Notice of Allowance From U.S. Patent and Trademark Office
Date:9/16/2009

PISCATAWAY, N.J., Sept. 16 /PRNewswire-FirstCall/ -- Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for Milestone's U.S. patent application, titled "Computer Controlled Drug Delivery System with Dynamic Pressure Sensing."

Dynamic Pressure Sensing provides visual and audible in-tissue pressure feedback, identifying tissue types to the healthcare provider. This feedback allows a healthcare provider to know when certain types of tissue have been penetrated, allowing for the injection of medicaments at a precise location. This is particularly beneficial when making subcutaneous and intramuscular injections.

Dr. Mark Hochman, Director of Clinical Affairs at Milestone Scientific, stated, "This Notice of Allowance is of profound significance to our Company, in that the noted intellectual property represents one of the key technological components that will afford Milestone Scientific the opportunity to enter the medical drug delivery market. Intra-articular, epidurals, along with numerous other injections should undergo a revolutionary change in the areas of efficacy, safety, and cost benefits."

A Notice of Allowance generally completes the substantive examination of a patent application. The normal process, which results in a final issuance of a U.S. patent, involves several administrative steps that are typically completed in due course following the issuance of such a Notice.

The new patent will provide protection for a key element of Milestone's technology until December 21, 2026 and thus will extend and strengthen Milestone's leadership position in the growing field of advanced injection and drug delivery systems. To date, Milestone has been awarded a total of 22 U.S. utility and design patents relating to its C-CLAD technologies. In August of this year, the Company received a Notice of Allowance for the bonded disposable hand piece for fluid administration used by the Company's commercially available C-CLAD systems, including the STA Single Tooth Anesthesia System(TM), CompuDent(R) and CompuMed(R).

"We are very proud of our Company's technological achievements and expect that the protection afforded by these patents will give Milestone a key competitive advantage in the drug delivery market," added Leonard Osser, Milestone's CEO. In June 2008, Business Insights reported that over the last decade, the drug delivery industry has evolved to become a key area in the development of value-added pharmaceutical products. The global market grew from $15 billion to $40 billion during 2000-2006 as companies increasingly turned to innovative new drug delivery technologies as a means of expanding product lifecycles, enhancing drug efficacy and maximizing revenues.

About Milestone Scientific Inc.

Headquartered in Piscataway, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company's IP platform and product development strategy is its patented CompuFlo(R) technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The STA Single Tooth Anesthesia System(TM), a computer-controlled local anesthesia delivery system, uses this technology to provide dentists with audible and visual signals as to in-tissue pressure. Milestone's existing painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company's web site found at www.milestonescientific.com and www.STAis4U.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of the Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2008. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

    FOR MORE INFORMATION, PLEASE CONTACT:
    Elite Financial Communications Group
    Dodi Handy, President and CEO (Twitter: @dodihandy)
    For Media Inquiries: Kathy Addison, Director, Elite Media Group (Twitter:
    @kathyaddison)
    407-585-1080 or via email at mlss@efcg.net


'/>"/>
SOURCE Milestone Scientific Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
2. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
3. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
4. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
5. Smurfit-Stones Hodge, LA, Mill Becomes First to Achieve Safety Milestone
6. Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization
7. Milestone Scientific to Present at the Edgewater Research Investor Conference
8. Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007
9. Global Gene Map Clears New Milestone
10. Free Site Offering Patient-Physician Dialog Reaches Milestone
11. Marlo Thomas and St. Jude Childrens Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: